Free tool
FDA Approval Tracker
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
186
2015 to 2026
Breakthrough
186
Accelerated
67
Priority review
174
Orphan
137
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2015 | 7 | 5 |
| 2016 | 6 | 3 |
| 2017 | 12 | 5 |
| 2018 | 10 | 8 |
| 2019 | 11 | 4 |
| 2020 | 15 | 8 |
| 2021 | 14 | 4 |
| 2022 | 9 | 7 |
| 2023 | 7 | 5 |
| 2024 | 12 | 6 |
| 2025 | 17 | 5 |
| 2026 | 2 | 4 |
186 approvals
Newest first. Hover a badge for what it means.
- Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INCJun 26, 2026
To treat thyroid eye disease
- Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
- Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
- Zycubo (Copper Histidinate) · Sentynl Theraps INCJan 12, 2026
To treat Menkes disease
- Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
- Jascayd (Nerandomilast) · Boehringer IngelheimDec 19, 2025
- Myqorzo (Aficamten) · CytokineticsDec 19, 2025
To treat symptomatic obstructive hypertrophic cardiomyopathy
- Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTDNov 25, 2025Original approval · BLA 761434NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression
- Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy
- Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
To reduce triglycerides in adults with familial chylomicronemia syndrome
- Komzifti (Ziftomenib) · KuraNov 13, 2025
To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options
- Kygevvi (Doxecitine, Doxribtimine) · Ucb INCNov 3, 2025
To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger
- Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
To treat idiopathic pulmonary fibrosis
- Inlexzo (Gemcitabine Hydrochloride) · Janssen BiotechSep 9, 2025
- Brinsupri (Brensocatib) · Insmed INCAug 12, 2025
To treat non-cystic fibrosis bronchiectasis
- Hernexeos (Zongertinib) · Boehringer IngelheimAug 8, 2025Original approval · NDA 219042NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy
- Zegfrovy (Sunvozertinib) · DizalJul 2, 2025Original approval · NDA 219839NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy
- Datroway (Datopotamab Deruxtecan-Dlnk) · Daiichi Sankyo INCJun 23, 2025Original approval · BLA 761464NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
- Yeztugo (Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
- Yeztugo (Lenacapavir, Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
- Ibtrozi (Taletrectinib Adipate) · NuvationJun 11, 2025
To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer
- Emrelis (Telisotuzumab Vedotin-Tllv) · Abbvie INCMay 14, 2025Original approval · BLA 761384NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy
- Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy
- Penpulimab-Kcqx (Penpulimab-Kcqx) · Akeso BiopharmaApr 23, 2025
In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy
- Vykat Xr (Diazoxide Choline) · SolenoMar 26, 2025
- Journavx (Suzetrigine) · Vertex Pharms INCJan 30, 2025
To treat moderate to severe acute pain
- Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INCDec 19, 2024
To treat familial chylomicronemia syndrome
- Crenessity (Crinecerfont) · NeurocrineDec 13, 2024
- Crenessity (Crinecerfont) · NeurocrineDec 13, 2024
To treat classic congenital adrenal hyperplasia
- Bizengri (Zenocutuzumab-Zbco) · Merus N.V.Dec 4, 2024Original approval · BLA 761352NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat non-small cell lung cancer and pancreatic adenocarcinoma
- Ziihera (Zanidatamab-Hrii) · Jazz PharmsNov 20, 2024Original approval · BLA 761416NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer
- Revuforj (Revumenib Citrate) · SyndaxNov 15, 2024
To treat relapsed or refractory acute leukemia
- Itovebi (Inavolisib) · Genentech INCOct 10, 2024
To treat locally advanced or metastatic breast cancer
- Miplyffa (Arimoclomol Citrate) · Zevra DenmarkSep 20, 2024
To treat Niemann-Pick disease type C
- Livdelzi (Seladelpar Lysine) · Gilead Sciences INCAug 14, 2024Original approval · NDA 217899NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat primary biliary cholangitis (PBC)
- Nemluvio (Nemolizumab-Ilto) · Galderma Labs LpAug 12, 2024
To treat prurigo nodularis
- Voranigo (Vorasidenib) · ServierAug 6, 2024
To treat Grade 2 astrocytoma or oligodendroglioma
- Kisunla (Donanemab-Azbt) · Eli Lilly COJul 2, 2024
To treat Alzheimer's disease
- Iqirvo (Elafibranor) · IpsenJun 10, 2024Original approval · NDA 218860NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat primary biliary cholangitis in combination with ursodeoxycholic acid
- Imdelltra (Tarlatamab-Dlle) · Amgen INCMay 16, 2024Original approval · BLA 761344NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat extensive stage small cell lung cancer
- Voydeya (Danicopan) · Alexion Pharms INCMar 29, 2024
To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria
- Winrevair (Sotatercept-Csrk) · Merck Sharp DohmeMar 26, 2024
To treat pulmonary arterial hypertension
- Rezdiffra (Resmetirom) · MadrigalMar 14, 2024Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
- Eohilia (Budesonide) · Takeda Pharms USAFeb 9, 2024
- Iwilfin (Eflornithine Hydrochloride) · UswmDec 13, 2023
- Fabhalta (Iptacopan Hydrochloride) · NovartisDec 5, 2023Original approval · NDA 218276NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat paroxysmal nocturnal hemoglobinuria
- Ogsiveo (Nirogacestat Hydrobromide) · SpringworksNov 27, 2023
To treat adults with progressing desmoid tumors who require systemic treatment
- Loqtorzi (Toripalimab-Tpzi) · Coherus Biosciences INCOct 27, 2023
To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.